Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A16AX16Orphan Medicine

Givlaari(Givosiran)

Porphyrias, Hepatic

Marketing Authorisation Holder: Alnylam Netherlands B.V.

EMA Authorisation: 02/03/2020

INN: givosiran

Indication

Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Givlaari — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.